AzTrials
AzTrials

Colorectal CancerKFTRNCT07923682

Outcomes of Knife-Assisted Full-Thickness Resection for Rectal Lesions: A Multicenter Study

An observational study of Colorectal Cancer, run by University Hospital, Ghent at 1 site in Belgium.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

This study looks at the results of a new technique called knife-assisted full-thickness resection (kFTR) for removing rectal lesions. In kFTR, a doctor uses an electrical knife to remove a rectal growth along with the full thickness of the rectal wall. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Colorectal Cancer
How many people
150 participants
Where
1 siteBelgium
Study dates
2 May 2025to 31 Dec 2029
Phase
Observational
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: Patients who underwent endoscopic knife-assisted full-thickness resection (kFTR) for rectal lesions at participating international centers

Who may be able to join

  • Patients aged 18 years and older
  • Knife-assisted full-thickness resection (kFTR) performed for a rectal lesion at a participating center

Who cannot join

  • Unavailable information regarding kFTR technical outcomes

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Belgium1 site, 1 recruiting
  • University Hospital Ghent

    Ghent, 9000

    David Tate, 093321063, studiestissue.resectie@uzgent.be

    Recruiting

Other trials in Belgium

About this study

Official title: Outcomes of Endoscopic Knife-Assisted Full-Thickness Resection for Rectal Lesions: An International Multicentre Retrospective Cohort Study

This study looks at the results of a new technique called knife-assisted full-thickness resection (kFTR) for removing rectal lesions. In kFTR, a doctor uses an electrical knife to remove a rectal growth along with the full thickness of the rectal wall. Current methods for removing early rectal tumors each have limits depending on the size and location of the growth. This study collects data from hospitals in multiple countries to find out how well kFTR works and how safe it is. Researchers review medical records and endoscopy reports from patients who already had kFTR at participating hospitals. The main measures are whether the procedure was completed successfully, whether the growth was removed in one piece, whether the edges were cancer-free, and how often complications occurred. The study also tracks hospital stay length, need for additional surgery, cancer recurrence, and death.

Read the detailed description

Background

Minimally invasive, organ-preserving techniques have become the preferred approach for early rectal cancer resection, replacing total mesorectal excision due to its high morbidity (12.1%-13.4%) and mortality (1%-1.5%). Recent meta-analysis data indicate that deep submucosal invasion is not an independent risk factor for lymph node metastasis in colorectal cancer (CRC), with 37.9% of deeply invasive cancers lacking other histologic high-risk features, making them suitable for curative endoscopic resection. However, current endoscopic techniques such as endoscopic submucosal dissection (ESD), Transanal Minimally Invasive Surgery (TAMIS), endoscopic device-assisted full-thickness resection (FTRD), and endoscopic intermuscular dissection (EID) have limitations in specific scenarios.

Endoscopic knife-assisted full-thickness resection (kFTR) has emerged as a novel technique for local excision of rectal lesions but remains under-evaluated in large cohort studies. The objective of this study is to assess the technical and clinical outcomes of kFTR for rectal lesions, including technical success, en-bloc and R0 resection rates, and the incidence of complications.

Study Endpoints

The primary outcomes of this study include technical success, en-bloc resection, and R0 resection rates. Additionally, complications such as intraprocedural and delayed bleeding, post-polypectomy syndrome, and other procedure-related adverse events will be evaluated. Secondary outcomes include the length of hospital stay, the need for adjunctive surgery due to complications or non-curative resections, locoregional or non-salvageable recurrence, and mortality.

Methods

This study follows a retrospective, international, multicenter cohort design. Eligible participants include patients aged 18 years or older who underwent kFTR at the participating centers. Cases with missing data on kFTR technical outcomes are excluded. Due to the limited availability of previous data on rectal kFTR, all eligible cases will be included without a predefined sample size calculation.

Data will be collected from electronic medical records, endoscopic images, and videos. Extracted patient characteristics include age, sex, comorbidities, ASA classification, prior neoadjuvant treatment, and preoperative staging. Lesion characteristics such as size, location, morphology (JNET and Paris classification), previous resection attempts, and fibrosis grade will also be recorded. Procedure-related variables include anesthesia type, dissection technique, defect closure, procedural success, procedural time, complications, and hospital stay. Histopathological data will be analyzed for tumor staging (pT), radicality, and high-risk features for nodal metastasis. Clinical outcomes such as adjuvant therapy, follow-up duration, recurrence, and mortality will be documented.

Variable Definitions

Technical success is defined as the completion of the procedure with lesion removal without conversion to another technique. Procedural time is measured from submucosal injection to procedure completion. Bleeding is classified as intraprocedural (requiring intervention) or delayed (occurring within 30 days post-procedure and necessitating medical intervention). Post-polypectomy syndrome is characterized by abdominal pain within 24 hours of the procedure that resolves with conservative management. Tumor budding is categorized into low (0-4 buds), intermediate (5-9 buds), and high (≥10 buds) groups. Metastases are classified as locoregional (spread to surrounding tissues or regional lymph nodes) or distant (e.g., liver, lung, peritoneum).

Statistical Analysis

Categorical variables will be presented as frequencies and percentages, while continuous variables will be reported as means (standard deviation) or medians (interquartile range), depending on data distribution. Subgroup analyses will assess effectiveness and safety outcomes based on lesion location, size, fibrosis, and resection technique. Comparisons between categorical variables will be conducted using chi-squared or Fisher's exact tests, while t-tests will be used for continuous variables.

Recurrence after resection will be analyzed over time using Kaplan-Meier survival analysis, with log-rank tests applied for group comparisons. Univariable analyses will assess associations between independent variables and key outcomes, including en-bloc resection, recurrence, and complications. Multivariable regression models will incorporate relevant variables to evaluate their independent associations with these outcomes. A p-value of ≤0.05 will be considered statistically significant. All statistical analyses will be performed using R software.

Data Management

Data will be anonymized, with each center maintaining a separate key linking patient identifiers to unique study IDs. Clinical data will be stored securely on UZ Gent servers and retained for 10 years following study completion before being permanently deleted. Access to the data will be restricted to study investigators.

Keywords
Colorectal Cancer, knife-assisted full-thickness resection, endoscopic resection, early rectal cancer, endoscopic submucosal dissection
Medical subject headings
Colorectal Neoplasms, Rectal Neoplasms

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Study groups in NCT07923682
Study groupRoleWhat they receive
kFTR RecipientsPatients aged 18 years and older who underwent endoscopic knife-assisted full-thickness resection (kFTR) for rectal lesions at participating international centers, with available data on technical outcomes.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Technical success rate

    Proportion of procedures completed with macroscopic lesion removal without conversion to another technique

    Measured: At the time of the procedure

  2. En-bloc resection rate

    Proportion of lesions removed in a single piece

    Measured: At the time of the procedure

  3. R0 resection rate

    Proportion of resections with histologically confirmed complete margin-free resection

    Measured: Within 2 weeks of the procedure (histopathology report)

  4. Rate of complications

    Composite of intraprocedural bleeding (requiring endoscopic treatment), delayed bleeding (requiring hospitalization, ED visit, or endoscopic/angiographic/surgical intervention within 30 days), post-polypectomy syndrome (abdominal pain within 24 hours resolving with conservative management), and other procedure-related complications

    Measured: Within 30 days of the procedure

Secondary outcomes (4)
  1. Length of hospital stay

    Duration of hospitalization following kFTR, measured in days

    Measured: Perioperative (from procedure to hospital discharge, up to 30 days)

  2. Rate of adjunctive surgery

    Proportion of patients requiring surgery for complications, failure after endoscopic resection, or non-curative resections

    Measured: Through study completion, up to end of follow-up (up to 7 years)

  3. Locoregional or non-salvageable recurrence rate

    Proportion of patients with cancer recurrence at or near the resection site, or distant recurrence not amenable to salvage therapy

    Measured: Through study completion, up to end of follow-up (up to 7 years)

  4. Mortality

    Death from any cause during follow-up

    Measured: Through study completion, up to end of follow-up (up to 7 years)

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted6 Nov 2026
  2. Study start2 May 2025
  3. Primary completion31 Dec 2029 (estimated)
  4. Study completion31 Dec 2029 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Retrospective
Enrolment
150 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07923682
Sponsor's protocol ID
ONZ-2025-0215
Acronym
KFTR
Status last verified
Nov 2026
First submitted
4 Jun 2026
Last updated
6 Nov 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

An observational study of Colorectal Cancer, run by University Hospital, Ghent at 1 site in Belgium.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 6 Nov 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Belgium. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact David Tate (093321063, studiestissue.resectie@uzgent.be), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Technical success rate (time frame: At the time of the procedure). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 Nov 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in